Preparation and evaluation of vancomycin spray-dried powders for pulmonary delivery

References

• Alexander MR. 1974. A review of vancomycin: after 15 years of use. Drug Intell Clin Pharm. 8(9):520–525.
   Google Scholar
• Amaro MI, Tewes F, Gobbo O, Tajber L, Corrigan OI, Ehrhardt C, Healy AM. 2015. Formulation, stability and pharmacokinetics of sugar-based salmon calcitonin-loaded nanoporous/nanoparticulate microparticles (NPMPs) for inhalation. Int J Pharm. 483(1–2):6–18.
   PubMedGoogle Scholar
• Aquino R, Prota L, Auriemma G, Santoro A, Mencherini T, Colombo G, Russo P. 2012. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells. Int J Pharm. 426(1-2):100–107.
   PubMed Web of Science ®Google Scholar
• Barazesh A, Gilani K, Rouini M, Barghi MA. 2018. Effect of pH and leucine concentration on aerosolization properties of carrier-free formulations of levofloxacin. Eur J Pharm Sci. 118:13–23.
   PubMed Web of Science ®Google Scholar
• Belotti S, Rossi A, Colombo P, Bettini R, Rekkas D, Politis S, Colombo G, Balducci AG, Buttini F. 2014. Spray dried amikacin powder for inhalation in cystic fibrosis patients: a quality by design approach for product construction. Int J Pharm. 471(1-2):507–515.
   PubMedGoogle Scholar
• Belotti S, Rossi A, Colombo P, Bettini R, Rekkas D, Politis S, Colombo G, Balducci AG, Buttini F. 2015. Spray-dried amikacin sulphate powder for inhalation in cystic fibrosis patients: the role of ethanol in particle formation. Eur J Pharm Biopharm. 93:165–172.
   PubMed Web of Science ®Google Scholar
• Bhatt JM. 2013. Treatment of pulmonary exacerbations in cystic fibrosis. Eur Respir Rev. 22(129):205–216.
   PubMedGoogle Scholar
• Brown SD, White R, Tobin P. 2017. Keep them breathing: cystic fibrosis pathophysiology, diagnosis, and treatment. JAAPA. 30(5):23–27.
   PubMedGoogle Scholar
• Carreno JJ, Kenney RM, Lomaestro B. 2014. Vancomycin-associated renal dysfunction: where are we now? Pharmacother. J Hum Pharmacol Drug Ther. 34(12):1259–1268.
   Google Scholar
• Cerchiara T, Abruzzo A, Di Cagno M, Bigucci F, Bauer-Brandl A, Parolin C, Vitali B, Gallucci M, Luppi B. 2015. Chitosan based micro- and nanoparticles for colon-targeted delivery of vancomycin prepared by alternative processing methods. Eur J Pharm Biopharm. 92:112–119.
   PubMed Web of Science ®Google Scholar
• Deming SN. 1991. Multiple-criteria optimization. J Chromatogr A. 550:15–25.
   Web of Science ®Google Scholar
• Douthit C, Gudenkauf B, Hamood A, Mudaliar N, Caroom C, Jenkins M. 2020. Effects of powdered rifampin and vancomycin solutions on biofilm production of Staphylococcus aureus on orthopedic implants. J Clin Orthop Trauma. 11:S113–S117.
   PubMedGoogle Scholar
• Eedara BB, Rangnekar B, Doyle C, Cavallaro A, Das SC. 2018. The influence of surface active l-leucine and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) in the improvement of aerosolization of pyrazinamide and moxifloxacin co-spray dried powders. Int J Pharm. 542(1–2):72–81.
   PubMedGoogle Scholar
• European Medicinal Agency. 2003. Stability testing guidelines: stability testing of new drug substances and products [ICH Q1(R2)].
   Google Scholar
• Farhangi M, Mahboubi A, Kobarfard F, Vatanara A, Mortazavi SA. 2019. Optimization of a dry powder inhaler of ciprofloxacin-loaded polymeric nanomicelles by spray drying process. Pharm Dev Technol. 24(5):584–592.
   PubMed Web of Science ®Google Scholar
• Fleming TR, O'Fallon JR, O'Brien PC, Harrington DP. 1980. Modified Kolmogorov-Smirnov test procedures with application to arbitrarily right-censored data. Biometrics. 36(4):607–625.
   Web of Science ®Google Scholar
• Flume PA, Mogayzel PJ, Jr Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC. 2009. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 180(9):802–808.
   PubMed Web of Science ®Google Scholar
• Focaroli S, Mah P, Hastedt J, Gitlin I, Oscarson S, Fahy J, Healy A. 2019. A Design of Experiment (DoE) approach to optimise spray drying process conditions for the production of trehalose/leucine formulations with application in pulmonary delivery. Int J Pharm. 562:228–240.
   PubMedGoogle Scholar
• Haj-Ahmad RR, Elkordy AA, Chaw CS, Moore A. 2013. Compare and contrast the effects of surfactants (PluronicF-127 and CremophorEL) and sugars (β-cyclodextrin and inulin) on properties of spray dried and crystallised lysozyme. Eur J Pharm Sci. 49(4):519–534.
   PubMed Web of Science ®Google Scholar
• Hassan D, Omolo CA, Fasiku VO, Mocktar C, Govender T. 2020. Novel chitosan-based pH-responsive lipid-polymer hybrid nanovesicles (OLA-LPHVs) for delivery of vancomycin against methicillin-resistant Staphylococcus aureus infections. Int J Biol Macromol. 147:385–398.
   PubMed Web of Science ®Google Scholar
• Hayes D Jr, Murphy BS, Mullett TW, Feola DJ. 2010. Aerosolized vancomycin for the treatment of MRSA after lung transplantation. Respirology. 15(1):184–186.
   PubMed Web of Science ®Google Scholar
• Hsu C-Y, Sung CT, Aljuffali IA, Chen C-H, Hu K-Y, Fang J-Y. 2018. Intravenous anti-MRSA phosphatiosomes mediate enhanced affinity to pulmonary surfactants for effective treatment of infectious pneumonia. Nanomedicine. 14(2):215–225.
   PubMed Web of Science ®Google Scholar
• Kadota K, Nishimura T, Hotta D, Tozuka Y. 2015. Preparation of composite particles of hydrophilic or hydrophobic drugs with highly branched cyclic dextrin via spray drying for dry powder inhalers. Powder Technol. 283:16–23.
   Web of Science ®Google Scholar
• Kaewjan K, Srichana T. 2016. Nano spray-dried pyrazinamide-l-leucine dry powders, physical properties and feasibility used as dry powder aerosols. Pharm Dev Technol. 21(1):68–75.
   PubMed Web of Science ®Google Scholar
• Karimi K, Katona G, Csóka I, Ambrus R. 2018. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride. J Pharm Biomed Anal. 148:73–79.
   PubMed Web of Science ®Google Scholar
• Karimi K, Pallagi E, Szabó-Révész P, Csóka I, Ambrus R. 2016. Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach. Drug Des Devel Ther. 10:3331–3343.
   PubMed Web of Science ®Google Scholar
• Kozáková J, Altay A, Ždímal V, Mašková L, Sonvico F, Quarta E, Rossi A, Buttini F, Colombo G. 2019. Dry powder inhaler of colistimethate sodium for lung infections in cystic fibrosis: optimization of powder construction. Drug Dev Ind Pharm. 45(10):1664–1625.
   PubMed Web of Science ®Google Scholar
• Kumar Padhi B, Chougule MB, Misra A. 2006. Optimization of formulation components and characterization of large respirable powders containing high therapeutic payload. Pharm Dev Technol. 11(4):465–475.
   PubMed Web of Science ®Google Scholar
• Lamy B, Serrano DR, O’connell P, Couet W, Marchand S, Healy AM, Tewes F. 2019. Use of leucine to improve aerodynamic properties of ciprofloxacin-loaded maltose microparticles for inhalation. Eur J Pharm Res. 1(1):02–11.
   Google Scholar
• Lechanteur A, Evrard B. 2020. Influence of composition and spray-drying process parameters on carrier-free DPI properties and behaviors in the lung: a review. Pharmaceutics. 12(1):55.
   Web of Science ®Google Scholar
• Lee C-P, Huang M-NL. 2021. D-optimal designs for second-order response surface models with qualitative factors. J Data Sci. 9(2):139–153.
   Google Scholar
• Lin Y, Chang RYK, Britton WJ, Morales S, Kutter E, Li J, Chan H-K. 2019. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections. Eur J Pharm Biopharm. 142:543–552.
   PubMed Web of Science ®Google Scholar
• Liu C, Lin L, Huang Z, Wu Q, Jiang J, Lv L, Yu X, Quan G, Li G, Wu C. 2019. Novel inhalable ciprofloxacin dry powders for bronchiectasis therapy: Mannitol-Silk fibroin binary microparticles with high-payload and improved aerosolized properties. AAPS PharmSciTech. 20(2):85.
   PubMed Web of Science ®Google Scholar
• Lu W, Rades T, Rantanen J, Yang M. 2019. Inhalable co-amorphous budesonide-arginine dry powders prepared by spray drying. Int J Pharm. 565:1–8.
   PubMedGoogle Scholar
• Martiniano SL, Hoppe JE, Sagel SD, Zemanick ET. 2014. Advances in the diagnosis and treatment of cystic fibrosis. Adv Pediatr. 61(1):225–243.
   PubMedGoogle Scholar
• Maselli D, Keyt H, Restrepo M. 2017. Inhaled antibiotic therapy in chronic respiratory diseases. IJMS. 18(5):1062.
   Google Scholar
• Mathew M, Gupta VD. 1995. Stability of vancomycin hydrochloride solutions at various pH values as determined by high-performance liquid chromatography. Drug Dev Ind Pharm. 21(2):257–264.
   Web of Science ®Google Scholar
• Momin MA, Sinha S, Tucker IG, Das SC. 2019. Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis. Drug Dev Ind Pharm. 45(8):1321–1311.
   PubMed Web of Science ®Google Scholar
• Momin MA, Tucker IG, Das SC. 2018. High dose dry powder inhalers to overcome the challenges of tuberculosis treatment. Int J Pharm. 550(1-2):398–417.
   PubMedGoogle Scholar
• Momin MA, Tucker IG, Doyle CS, Denman JA, Sinha S, Das SC. 2018. Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections. Int J Pharm. 541(1–2):26–36.
   PubMedGoogle Scholar
• Momin MAM, Tucker IG, Doyle CS, Denman JA, Das SC. 2018. Manipulation of spray-drying conditions to develop dry powder particles with surfaces enriched in hydrophobic material to achieve high aerosolization of a hygroscopic drug. Int J Pharm. 543(1–2):318–327.
   PubMedGoogle Scholar
• Morgan M. 2011. Treatment of MRSA soft tissue infections: an overview. Injury. 42:S11–S17.
   PubMed Web of Science ®Google Scholar
• Nagahama Y, VanBeek MJ, Greenlee JD. 2018. Red man syndrome caused by vancomycin powder. J Clin Neurosci. 50:149–150.
   Google Scholar
• Nguyen DQ, Mounir S, Allaf K. 2017. Optimization of the spray drying operating conditions for producing the powder mixture of gum Arabic and maltodextrin. Int J Food Eng. 13(8):20160271.
   Web of Science ®Google Scholar
• Ógáin ON, Li J, Tajber L, Corrigan OI, Healy AM. 2011. Particle engineering of materials for oral inhalation by dry powder inhalers. I-Particles of sugar excipients (trehalose and raffinose) for protein delivery. Int J Pharm. 405(1–2):23–35.
   PubMedGoogle Scholar
• Organization WH. 2018. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. WHO Tech Rep Ser. 953:87–123.
   Google Scholar
• Parsian AR, Vatanara A, Rahmati MR, Gilani K, Khosravi KM, Najafabadi AR. 2014. Inhalable budesonide porous microparticles tailored by spray freeze drying technique. Powder Technol. 260:36–41.
   Web of Science ®Google Scholar
• Pourshahab PS, Gilani K, Moazeni E, Eslahi H, Fazeli MR, Jamalifar H. 2011. Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid. J Microencapsul. 28(7):605–613.
   PubMed Web of Science ®Google Scholar
• Rossi I, Buttini F, Sonvico F, Affaticati F, Martinelli F, Annunziato G, Machado D, Viveiros M, Pieroni M, Bettini R. 2019. Sodium hyaluronate nanocomposite respirable microparticles to tackle antibiotic resistance with potential application in treatment of mycobacterial pulmonary infections. Pharmaceutics. 11(5):203.
   PubMed Web of Science ®Google Scholar
• Schoubben A, Vivani R, Paolantoni M, Perinelli DR, Gioiello A, Macchiarulo A, Ricci M. 2019. D-leucine microparticles as an excipient to improve the aerosolization performances of dry powders for inhalation. Eur J Pharm Sci. 130:54–64.
   PubMed Web of Science ®Google Scholar
• Serri A, Moghimp HR, Mahboubi A, Zarghi A. 2017. Stability-indicating HPLC method for determination of vancomycin hydrochloride in the pharmaceutical dosage forms. Acta Pol Pharm. 74(1):73–79.
   PubMed Web of Science ®Google Scholar
• Shah M, Pore Y, Dhawale S, Burade K, Kuchekar B. 2013. Physicochemical characterization of spray dried ternary micro-complexes of cefuroxime axetil with hydroxypropyl-β-cyclodextrin. J Incl Phenom Macrocycl Chem. 76(3–4):391–401.
   Web of Science ®Google Scholar
• Sibum I, Hagedoorn P, Frijlink HW, Grasmeijer F. 2019. Characterization and formulation of isoniazid for high-dose dry powder inhalation. Pharmaceutics. 11(5):233.
   PubMed Web of Science ®Google Scholar
• Stass H, Nagelschmitz J, Kappeler D, Sommerer K, Patzlaff A, Weimann B. 2019. Ciprofloxacin dry powder for inhalation: inspiratory flow in patients with non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv. 32(3):156–163.
   PubMed Web of Science ®Google Scholar
• Takács-Novák K, Noszál B, Tókés-Kövesdi M, Szász G. 1993. Acid-base properties and proton-speciation of vancomycin. Int J Pharm. 89(3):261–263.
   Web of Science ®Google Scholar
• Telko MJ, Hickey AJ. 2005. Dry powder inhaler formulation. Respir Care. 50(9):1209–1227.
   PubMedGoogle Scholar
• Wang F, Wang C-H. 2002. Effects of fabrication conditions on the characteristics of etanidazole spray-dried microspheres. J Microencapsul. 19(4):495–510.
   PubMed Web of Science ®Google Scholar
• Weers JG, Miller DP, Tarara TE. 2019. Spray-Dried PulmoSphere™ formulations for inhalation comprising crystalline drug particles. AAPS PharmSciTech. 20(3):103.
   PubMed Web of Science ®Google Scholar
• Yang X-F, Xu Y, Qu D-S, Li H-Y. 2015. The influence of amino acids on aztreonam spray-dried powders for inhalation. Asian J Pharm Sci. 10(6):541–548.
   Web of Science ®Google Scholar
• Ye T, Sun S, Sugianto TD, Tang P, Parumasivam T, Chang YK, Astudillo A, Wang S, Chan H-K. 2018. Novel combination proliposomes containing tobramycin and clarithromycin effective against Pseudomonas aeruginosa biofilms. Int J Pharm. 552(1–2):130–138.
   PubMed Web of Science ®Google Scholar
• Zarif M, Afidah A, Abdullah J, Shariza A. 2012. Physicochemical characterization of vancomycin and its complexes with beta-cyclodextrin. Biomed Res. 23(4):513–520.
   Google Scholar
• Zhao Z, Zhang X, Cui Y, Huang Y, Huang Z, Wang G, Liang R, Pan X, Tao L, Wu C. 2019. Hydroxypropyl-β-cyclodextrin as anti-hygroscopicity agent inamorphous lactose carriers for dry powder inhalers. Powder Technol. 358:29–38.
   Web of Science ®Google Scholar
• Zhou QT, Leung SSY, Tang P, Parumasivam T, Loh ZH, Chan H-K. 2015. Inhaled formulations and pulmonary drug delivery systems for respiratory infections. Adv Drug Deliv Rev. 85:83–99.
   PubMed Web of Science ®Google Scholar